Skip to main content

Olfactory, Gustatory Dysfunction Decline in Years Following COVID-19

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 15, 2023.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Nov. 15, 2023 -- The prevalence of olfactory dysfunction (OD) and gustatory dysfunction (GD) declines in the three years after COVID-19 infection, according to a research letter published online Nov. 9 in JAMA Otolaryngology-Head & Neck Surgery.

Paolo Boscolo-Rizzo, M.D., from the University of Trieste in Italy, and colleagues estimated the three-year prevalence of measured OD and GD associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. One-hundred individuals who tested positive for SARS-CoV-2 were matched with 100 controls recruited from hospital staff who tested negative for SARS-CoV-2. Eighty-eight cases completed all follow-up assessments.

The researchers found that during the acute phase of COVID-19 and at one-, two-, and three-year follow-up, the prevalence of self-reported smell or taste dysfunction was 64.8, 31.8, 20.5, and 15.9 percent, respectively, among cases. The prevalence of OD decreased during follow-up, with frequency of 40.9, 27.3, and 13.6 percent of one-, two-, and three-year evaluations, respectively. Cases were more likely to have OD than controls at two years after infection (27.3 versus 10.2 percent); however, at three years after COVID-19, no significant excess of OD was identified (13.6 and 10.2 percent, respectively). At one-, two-, and three-year evaluation, the prevalence of GD was 26.1, 13.6, and 11.4 percent, respectively; at two and three years after COVID-19, there were no differences in GD observed between cases and controls.

"Patients with post-COVID-19 condition exhibiting chemosensory alterations should be reassured that a recovery of olfaction appears to continue over three years after initial infection," the authors write.

One author disclosed ties to the biopharmaceutical, medical device, and nutrition industries.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes

MONDAY, June 3, 2024 -- Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events...

Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season

WEDNESDAY, May 22, 2024 -- In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for...

Global Life Expectancy, Disease Burden Set to Keep Improving

WEDNESDAY, May 22, 2024 -- Life expectancy and age-standardized disease burden are expected to continue improving between 2022 and 2050, according to the Global Burden of Disease...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.